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The renal response to atrial natriuretic factor is 
blunted in cirrhosis with ascites. This might be due to 
alterations of renal receptors for atrial natriuretic 
factor. Therefore density and affinity of glomerular 
atrial natriuretic factor binding sites of bile duct- 
ligated rats with ascites (n = 10) and of sham-operated 
controls (n = 10) were determined. Glomerular atrial 
natriuretic factor binding sites were identified to be of 
the B-(“biologically active”) and C-(“clearance”) re- 
ceptor type. Discrimination and quantitative determi- 
nation of B and C receptors for atrial natriuretic factor 
were achieved by displacement experiments with 
atrial natriuretic factor(99-126) or des(l8-22)atrial 
natriuretic factor(4-23), an analogue binding to C 
receptors only. Density of total glomerular atrial na- 
triuretic factor binding sites was significantly in- 
creased in bile duct-ligated rats (3,518 * 864 vs. 
1,648 2 358 fmol/mgprotein; p < 0.05). This was due to 
a significant increase of C-receptor density (3,460 f 
866 vs. 1,486 f 363 fmol/mg protein; p < 0.05), whereas 
density of B receptors was not significantly different in 
bile duct-ligated rats (58 2 11 vs. 162 2 63 fmol/mg 
protein). Affinity of atrial natriuretic factor to its 
glomerular binding sites did not differ significantly 
between both groups. These data suggest that an 
altered glomerular atrial natriuretic factor receptor 
density could be involved in the renal resistance to 
atrial natriuretic factor in cirrhosis with ascites. 
(HEPATOLOCY 1991;13:562-566.) 
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Atrial natriuretic factor (ANF) is a hormone inti- 
mately involved in the regulation of body fluid and 
electrolyte balance (1-5). ANF induces natriuresis and 
diuresis by interaction with specific renal receptors. 
Lately, the presence of two distinct ANF receptor types 
has been demonstrated: The B and C receptors (6-9): 
The B receptor has a molecular weight of about 130 kD, 
exhibits a high affinity to circulating ANF and is 
considered to mediate the biological actions of ANF by 
activating particulate guanylate cyclase, which is part of 
its intracellular domain. It has thus been called “B” (for 
biologically active) receptor. The difference in structural 
requirements for binding of ANF ligands allows for 
quantitative discrimination from the B receptor. This 
binding site removes ANF from the circulation without 
inducing apparent biological actions and has thus been 
termed “C” (for clearance) receptor. The C receptor has 
a molecular weight of about 65 kD, binds circulating 
ANF with lower affinity but also binds truncated analogs 
of ANF. 
Alterations of total glomerular ANF receptor density 
have been demonstrated after changes of body fluid 
volume (10-12). Recently, we have shown that physio- 
logical changes of body fluid volume affect density of 
both receptor subtypes on glomerular membranes to a 
different extent (13). Therefore it is important to 
discriminate between B and C receptors also when 
investigating the ANF receptor status in a pathophysi- 
ological state. 
Renal response to ANF has been shown to be blunted 
in patients with cirrhosis and in rat models of cirrhosis 
(14-21). This renal resistance to circulating and to 
exogenously administered ANF in cirrhosis might be due 
to an alteration of ANF receptor density. Therefore in 
this study we investigated both types of ANF binding 
sites in renal glomeruli of cirrhotic rats. 
MATERIALS AND METHODS 
Animals. Male Sprague-Dawley rats (300 to 320 g m )  were 
subjected to bile duct ligation and division (22). In the control 
group, animals were sham-operated with visualization of the 
bile duct. The rats were fed with regular pelleted chow and tap 
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water. Approximately 6 wk after bile duct ligation, rats with 
evidence of ascites were decapitated, trunk blood was collected 
in precooled EDTA tubes (1 mg/ml) and the kidneys were 
rapidly excised. Ten bile duct-ligated (BDL) animals with 
ascites were compared with 10 sham-operated controls 
(SHAM). 
RLA for ANF. Blood samples were centrifuged at 1,500 g for 
10 min at  4" C and the plasma was stored at  - 70" C until assay. 
Extraction of plasma samples and RIA procedures were 
modified from previously reported procedures (17,23). Briefly, 
200 ~1 plasma samples were extracted by adsorption to 
activated Amberlite XAD-2 adsorbent resin (particle size 0.3 to 
1.0 mm, Serva, Heidelberg, FRG) and eluted with acetoni- 
trile/O.l% trifluoroacetic acid (80%/20%). Recovery was 70% 
and the detection limit of the RIA was 0.5 f m o h b e .  
Preparation of Glomerular Membranes. Rat glomeruli were 
isolated according to a graded sieving method (24) with some 
modifications. Kidneys were cut longitudinally, the medulla 
was removed and the cortical tissue was filtered through 
250 pm, 140 pm and 75 pm sieves. Glomeruli were then 
suspended in ice-cold PBS, pH 7.5, and centrifuged (10,000 g, 
4" C, 10 rnin). Membranes were prepared by resuspending the 
glomeruli in 50 mmol/L Tris-HC1, pH 7.4, 1 mmol/L NaHCO, 
and by homogenizing with a Polytron (Kinematica, Littau, 
Switzerland) at  4" C, setting 6 for 3 x 20 sec. The homogenate 
was diluted (1 : 1) with 50 mmoVL Tris-HC1, pH 7.4, 1 mmol/L 
EDTA, 1 mmol/L MgC1, and sedimented at 30,OOOg for 15 min 
at  4" C. The pellet was washed once and resuspended in 50 
mmoVL Tris-HC1, pH 7.4, 250 mmol/L sucrose. The mem- 
branes were frozen and stored at -70" C. Protein concen- 
tration was determined by the method of Lowry et  al. (25) 
using BSA as standard. 
Binding h a y .  Binding studies were performed in triplicate 
at 4" C for 5 hr in a HEPES buffer, as described elsewhere (13, 
26). Incubation volume was 0.5 ml. 1251-rANF(99-126) 
(Biotrend, Koln, FRG; specific activity 2,200 Ci/mmol) concen- 
tration was 20 pmol/L. For competitive binding, the unlabeled 
peptides rANF(99-126) (Novabiochem, Laufelfingen, Swit- 
zerland) or des( 18-22)-rANF(4-23)-NH2, a truncated ANF 
analogue that binds to C receptors only (91, were present in 
increasing concentrations (lo-'' to mol/L). Binding 
reactions were initiated by adding 15 pg of glomerular 
membrane protein. Reactions were stopped by dilution with 
2.5 ml ice-cold 50 mmol/L Tris-HC1, pH 7.4, and rapid filtration 
through 1% polyethyleneimine-treated Whatman GF/C filters 
(Whatman, Maidstone, United Kingdom). Filters were washed 
with 5 ml 50 mmol/L Tris-HC1, pH 7.4, allowed to dry and 
radioactivity was measured in an LKB 1261 Multigamma 
counter (LKB, Turku, Finland) with 80% efficiency. 
Aftfnity Cross-linking of ANF Receptors. Thirty micrograms 
glomerular membrane protein were incubated for 5 hr at 4" C 
with 60 pmol/L 1261-rANF(99-126) in the presence or absence 
of unlabeled rANF(99-126) or of des( 18-22)-rANF(4-23)-NH2. 
After incubation, the membranes were washed, resuspended in 
ice-cold PBS buffer, pH 7.5, and incubated with 0.1 mmol/L 
bis(sulfosuccinimidy1)suberate (Pierce, Beijerland, The Neth- 
erlands) for 25 min at  4" C. The reaction was quenched by 
adding 10 mmol/L ammonium acetate and the membranes 
were centrifuged in an Eppendorf centrifuge for 7 min. The 
pellet was resuspended in 30 pl sample buffer (62 mmoVL 
Tris-HC1, pH 6.8, 2% SDS, 10% glycerol, 0.001% bromphenol 
blue) containing 5% 2-mercaptoethanol and heated for 3 min 
at  100" C. Membrane proteins were separated on a 7.5% 
SDS-PAGE under constant voltage conditions (Hoefer Sci- 
entific Instruments, San Francisco, CA). Standard molecular 
weight markers were used for calculation of molecular weights 
TABLE 1. B, and K, of glomerular ANF binding sites in 
BDL rats with ascites and in SHAM rats" 
Variable 
SHAM rata BDL rata 
n = 10 n = 10 
~ 
ANF plasma concentration 7.6 2 1.3 8.1 -c 2.1 




B, (fmoUmg protein) 162 2 63 58 2 11 
K, (pmoUL) 96 2 49 23 2 8 
B, (fmoUmg protein) 1,486 2 363 3,460 2 866' 
K, (pmoUL) 693 2 175 1,116 2 293 
C receptor 
"B,, = density; K, = affinity. 
*Significant difference (p c 0.05) to SHAM rats. 
of labeled bands (Serva, Heidelberg, FRG). Gels were stained, 
dried and exposed to Kodak X-OMAT AR film with a Kodak 
X-OMAT regular enhancing screen (Eastman Kodak, Roch- 
ester, NY) at - 70" C for 2 to 3 wk. 
Analysis of Data. The results are expressed as mean +- S.E. 
Binding data were analyzed using the LIGAND program (27) 
to determine the density and affinity of binding sites from 
competitive experiments. Data of BDL animals were compared 
with SHAM controls by Student's t test; a p value of 0.05 or less 
was considered statistically significant. 
RESULTS 
Quantification of ANF Receptor Binding Sites. For 
the present study only BDL rats with ascites were 
selected. As shown in Table 1, these animals had similar 
ANF plasma concentrations as the control rats (8.7 2 
2.1 vs. 7.6 & 1.3 fmol/ml). The biphasic shape of 
competition binding curves with rANF(99-1261, binding 
to B and to C receptors (Fig. 1, upper panel) suggested 
the presence of two different binding sites. Competition 
binding with the ANF analogue binding to C receptors 
only (Fig. 1, lower panel) showed a monophasic curve, 
displacing less of the labeled peptide at  excess concen- 
trations than rANF(99-126). Thus there were probably 
B and C receptors present on glomerular membranes, 
with the majority of the C type. Analysis of competition 
binding curves t o  glomerular membranes (Fig. 1) 
showed that the total receptor density was significantly 
increased (3,518 ? 864 vs. 1,648 & 358 fmoVmg pro- 
tein; p < 0.05) in BDL rats (Table 1). Quantification of 
both receptor types demonstrated that this increase was 
due to a significant augmentation of the C receptor 
population in the BDL animals (3,460 f 866 vs. 
1,486 2 363 fmoVml protein; p c 0.05). The density of 
B receptors tended to be decreased, however not signif- 
icantly so (58 k 11 vs. 162 -+ 63 fmoVmg protein). 
There was no significant difference in affinity of B or 
C receptors to ANF between BDL and SHAM rats 
(Table 1). 
Molecular Weight Characterization of ANF Binding 
Sites. The presence of glomerular ANF binding sites was 
confirmed and their molecular weight characterization 
was performed by affinity cross-linking studies in SHAM 
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FIG. 1. Representative competition binding curves of Iz5II-rANF to 
glomerular membranes. Membranes from (0 )  BDL and (3)  SHAM rats 
were incubated in triplicate with increasing concentrations of unla- 
beled rANF(99-126) binding to B and C receptors (A) or des(18-22)- 
rANF(4-23) binding to C receptors only (B). Results are expressed as 
boundtotal vs. total (unlabeled peptide). 
and in BDL rats. Autoradiography of the dried gel of 
glomerular membrane preparations from both BDL rats 
and controls showed two bands with the apparent 
molecular weights of 65 kD, as reported for the C 
receptor, and 130 kD, as demonstrated for the B receptor 
(Fig. 2A). Displacement with increasing concentrations 
of unlabeled ANF proved the specificity of lZ5I-rANF 
cross-linking (Fig. 2B). Excess concentrations (10 - 6  
mol/L) of the truncated analogue, binding to the C 
receptor only, displaced the band at 65 kD but not the 
band at 130 kD (Fig. 2C). 
Thus the two ANF binding sites determined under our 
experimental conditions were most likely identified as B 
and C receptors. 
DISCUSSION 
In this study, we found an altered density of ANF 
binding sites on renal glomeruli of cirrhotic rats. Bile 
FIG. 2. Autoradiogram of SDS-PAGE-resolved glomerular mem- 
brane protein after cross-linking with '"'I-rANF, which binds to both 
B and C receptors. (A) Labeled bands are at 130 kD and 65 kD (the 
motilities of molecular weight standards are shown at  the right side 
of the gel) in glomerular membranes from RDL rats (lanes 4 to 61 
and SHAM (lanes 1 to 3). The bands correspond to the molecular 
weight of the R receptor (130 kD) and the C receptor (65 kD), 
respectively. (B) Labeled bands (glomeruli from control rats) at 130 
kD and 65 kD are both displaced with increasing concentrations of 
unlabeled rANF(99-126), which binds to B and C receptors. This 
finding demonstrates specific labeling of the bands as ANF binding 
sites. (C) The band a t  65 kD, but not the band at  130 kD (glomeruli 
from control rats), is displaced by 10 6mol/'L des(18-22)-rANF(4- 
23)-NH,, a truncated ANF analogue that binds to C receptors only. 
Altogether these data most likely characterize the binding sites 
determined as B and C receptors. 
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duct ligation was chosen as a rat model of cirrhosis; to 
assure an advanced stage with massive sodium re- 
tention, only animals with marked ascites were investi- 
gated. 
The two types of ANF binding sites, identified on 
glomerular membranes, most likely correspond to the B 
and C receptors. This conclusion is supported by the 
following observations: (a) Competitive binding curves 
with the unlabeled ligand ANF(99-126), binding to both 
receptors, exhibited a biphasic shape and computerized 
analysis continuously yielded better fits for two than for 
one binding site. Furthermore, displacement with the 
truncated analogue, binding to C receptors only, showed 
just one class of receptors (Fig. 1). (b) Resolutions of 
glomerular membranes by SDS-PAGE after cross- 
linking to 12"I-rANF showed two specifically labeled 
bands at 65 kD and 130 kD, corresponding to the 
reported molecular weight of the C and B receptor, 
respectively, with the truncated analogue displacing the 
65 kD band only (Fig. 2). 
The density of total ANF binding sites was markedly 
increased in BDL rats compared with controls. These 
findings are in accordance with the observation of 
increased glomerular ANF receptor density in BDL rats 
by Morgan et al. (28). These authors, however, while 
finding a blunted cGMP generation, did not differentiate 
ANF receptor types. Discrimination of both ANF re- 
ceptors showed that the increased receptor density in 
our experiments was due to a twofold augmented 
number of C receptors. B-receptor density was not 
significantly decreased in BDL rats. The ratio of B to C 
receptors was eminently reduced in BDL animals. 
Thus a given dose of ANF would be less effective in the 
kidney of cirrhotic compared with control animals: 
the proportion of ANF reaching the B receptors would 
be reduced; moreover, the number of B receptors, 
linking ANF to its biological effects, tended to be 
decreased. 
Because the changes of density of ANF receptors in 
cirrhosis were accompanied by a tendency of inverse 
alterations of affinity, there might be doubts about the 
biological net result of these changes. However, several 
observations are against such an interpretation: Recip- 
rocal changes of binding capacity and affinity of ANF to 
glomeruli have often been described (11, 12, 29) (e.g., a 
3.5-fold increase of receptor density after a low salt diet 
accompanied by a 2.5-fold decrease of affinity) (10). 
Contrary to the hypothesis that this lowering of the 
affinity would tend to oppose the augmented receptor 
density, greater ANF binding was observed in this group 
of animals at any given ANF concentration (10). Thus, 
it seems that changes in receptor density outweigh 
changes in affinity. Furthermore, to eliminate possible 
influences of affinity on the calculated receptor density, 
we additionally performed a simultaneous fit of the 
binding data of both groups and calculations with the 
same, shared affinity for all animals with the LIGAND 
program (27). Both approaches yielded similar results as 
those generated by individual fits shown in Table 1. 
Thus using various analytical procedures, C-receptor 
density was constantly found to be significantly aug- 
mented in cirrhosis. 
Why was glomerular density of ANF receptors 
changed in the cirrhotic rats? Because little information 
is available on the regulation of B and C receptors for 
ANF by physiological stimuli and this is the first 
communication about the influence of a pathophysio- 
logical condition on the ANF receptor status, the 
question can hardly be answered. Increased density of 
glomerular ANF binding sites has been observed on 
dehydration or low salt diet (10-12). We could recently 
demonstrate that dehydration selectively increases C 
receptors with no effect on B-receptor density (13). This 
change was accompanied by a decrease of ANF plasma 
concentration. In the present investigation, however, 
cirrhotic rats exhibited increased C-receptor density at 
ANF plasma concentrations not different from those of 
control rats. Therefore changes of ANF receptor density 
in the BDL animals cannot be explained by different 
concentrations of circulating ANF. Thus expression of 
glomerular ANF receptors is altered in cirrhosis by a 
mechanism that remains to be elucidated. 
Actually, renal response to endogenously released and 
to exogenously administered ANF is blunted in cirrhosis 
(for review see references 30 and 31). Several factors, 
such as a decrease of blood pressure or an activation of 
sodium-retaining systems after the administration of 
ANF, might be involved therein (18,20,32). However, as 
demonstrated by our study, alterations of renal ANF 
receptor density might also contribute to the renal 
resistance to ANF. The present investigation, for the 
first time quantitatively determining renal B and C 
receptors for ANF in a pathophysiological state, shows 
an increased number of clearance receptors in the BDL 
model of cirrhosis. Thus alterations of renal ANF 
binding sites indeed could contribute to the observed 
resistance to ANF in cirrhosis. 
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